Table 3.
No fibrillation (n = 482) |
Fibrillation (n = 238) |
||||
---|---|---|---|---|---|
Laboratory test | No. (%) of subjects who had tests |
No. of tests per subject, mean (SD) |
No. (%) of subjects who had tests |
No. of tests per subject, mean (SD) |
P* |
Total no. of tests per patient |
482 (100) | 38.4 (16.6) | 238 (100) | 53.7 (29.5) | <.001 |
Blood chemistry assays | 481 (99.8) | 11.8 (10.1) | 238 (100) | 23.0 (17.7) | <.001 |
Hematologic tests | 481 (99.8) | 10.7 (4.6) | 238 (100) | 13.5 (8.3) | <.001 |
Prothrombin and partial thromboplastin times |
180 (37.3) | 1.5 (0.9) | 109 (45.8) | 2.3 (2.2) | .001 |
Arterial blood gas analyses |
478 (99.2) | 4.0 (1.2) | 238 (100) | 4.2 (1.6) | .009 |
Procainamide/ N-acetylprocainamide levels |
3 (0.6) | 2 (0) | 133 (55.9) | 3.6 (2.6) | .28 |
Quinidine level | 0 (0) | 0 (0) | 3 (1.3) | 1.7 (0.6) | ND |
Digoxin level | 0 (0) | 0 (0) | 4 (1.7) | 1.3 (1.3) | ND |
ND indicates that statistical analysis was not done because of the small number of subjects for whom this test was ordered.
P values are based on comparison of data for no. of tests per subject.